This article appears in the following Journal of Antimicrobial Chemotherapy issue: Daptomycin development and clinical experience [View the issue table of contents]
Articles |
Clinical experience with daptomycin: bacteraemia and endocarditis
Division of General Internal Medicine, Wayne State University, University Health Center, Suite 5C, 4201 St Antoine, Detroit, MI 48201, USA
* Tel: +1-313-577-7935; Fax: +1-313-745-4707; E-mail: dlevine{at}med.wayne.edu
Serious infections due to Staphylococcus aureus, especially those due to methicillin-resistant S. aureus, have become a major challenge. Vancomycin has long been the drug of choice for treatment of such infections, but failures due to its slow bactericidal activity coupled with increasing MICs have necessitated a search for new, more effective agents. Daptomycin has been studied by a number of investigators and has proved to be effective for bacteraemic infections due to staphylococci as well as vancomycin-resistant enterococci and other Gram-positive organisms. In addition, in a randomized controlled trial comparing daptomycin monotherapy with potentially synergistic therapy with either vancomycin or β-lactam, both used in combination with an aminoglycoside, daptomycin achieved comparable outcomes but with significantly less nephrotoxicity.
Keywords: MRSA , Staphylococcus aureus , S. aureus
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. M. Gould Who's winning the war? J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii3 - iii6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Hawkey Pre-clinical experience with daptomycin J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii7 - iii14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Warren Daptomycin in endocarditis and bacteraemia: a British perspective J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii25 - iii33. [Abstract] [Full Text] [PDF]
|
|